+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Antibody Drug Conjugate Market Analysis: By Phase By Availability and By Geography - With Forecast 2016-2021

  • ID: 3920154
  • Report
  • 133 pages
  • IndustryARC
1 of 3
Antibody drug conjugates (ADCs) are a new class of therapeutic agents, gaining increasing attention from both large and small pharmaceutical companies. Antibody drug conjugates is generally derived from the combination of an antibody with a toxic drug / chemotherapy drug, these conjugates are believed to be more efficient and effective in the treatment of a disease. Antibody drug conjugates also known as anti-cancer drugs are promising and effective modalities for cancer therapies and is prepared on two major principles of antibody resistance and cell killing efficiency of highly potent active pharmaceutical ingredient (HPAPI). This report is focused on identifying market size for antibody drug conjugate globally. Increasing cancer patients and instances globally coupled with increasing R&D activities in the field of cancer treatment is one of the major drivers for the growth of the antibody drug conjugate market.

This report identifies the antibody drug conjugate market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to antibody drug conjugate market.

Globally North America dominated market for antibody drug conjugate in 2015 due high investment in the field for cancer treatment, better medical infrastructure and better access to the population in the region. North America was followed by Europe and Asia-Pacific as the second and third largest markets respective in 2015. Demand for antibody drug conjugate in the Asia-Pacific region is estimated to be grow fastest during the period of study and is expected to be driven by developing medical infrastructure and various initiatives by government to provide better access to the people in the region. This report on global antibody drug conjugate also covers antibody drug conjugate market size by drug phase and available drug market and also based on various geographical regions.

On the basis of phase of drug availability anti-infective drug phase this report classified as follows : Clinical and Pre-Clinical

On the basis of availability of drugs global antibody drug conjugate market is segmented as follows: Approved Drugs (Adcetris, Kadcyla), Pipeline Drugs (T-DM1, CMC-544, CDX-011, SAR3419 and Others)
This report on global antibody drug conjugate is also classified on the basis of infection type covering all major types of infections as follows: HIV, Hepatitis B, Hepatitis C, Urinary Tract, Respiratory Candidiasis and Other Infections
This is report has been further segmented into major regions, which includes detailed analysis of each region such as North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets for antibody drug conjugate in each of the region.

This report identifies all the major companies operating in the global antibody drug conjugate market. Some of the major companies’ profiles in detail are as follows:

Seattle Genetics
Bayer HealthCare AG
Pfizer Inc.
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
Note: Product cover images may vary from those shown
2 of 3
1. Antibody Drug Conjugate – Market Overview

2. Executive Summary

3. Antibody Drug Conjugate Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.2.1. Product Benchmarking
3.2.2. End User Profiling
3.2.3. Top 5 Financials Analysis

4. Antibody Drug Conjugate – Market Forces
4.1. Drivers
4.1.1. Extensive R&D and rising incidences of various cancers
4.2. Restraints
4.2.1. High cost of ADC drugs
4.2.2. Stringent regulations
4.3. Opportunities
4.4. Challenges
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition

5. Antibody Drug Conjugate – Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors

6. Global Antibody Drug Conjugate Market, By Phase (2014-2021)
6.1. Clinical
6.2. Pre-Clinical

7. Global Antibody Drug Conjugate Market, By Availability (2014-2021)
7.1. Approved Drugs
7.1.1. Adcetris
7.1.2. Kadcyla
7.2. Pipeline Drugs
7.2.1. T-DM1
7.2.2. CMC-544
7.2.3. CDX-011
7.2.4. SAR3419
7.2.5. Others

8. Global Antibody Drug Conjugate Market, By Geography (2014-2021)
8.1. Europe
8.1.1. Germany
8.1.2. France
8.1.3. Italy
8.1.4. Spain
8.1.5. Russia
8.1.6. U.K.
8.1.7. Rest of Europe
8.2. Asia Pacific
8.2.1. China
8.2.2. India
8.2.3. Japan
8.2.4. South Korea
8.2.5. Rest of Asia-Pacific
8.3. North America
8.3.1. U.S.
8.3.2. Canada
8.3.3. Mexico
8.4. Rest of the World (RoW)
8.4.1. Brazil
8.4.2. Rest of RoW

9. Antibody Drug Conjugate – Market Entropy
9.1. Expansion
9.2. Technological Developments
9.3. Merger & Acquisitions, and Joint Ventures
9.4. Supply- Contract

10. Company Profiles (Top 10 Companies)
10.1. ImmunoGen
10.1.1. Introduction
10.1.2. Financials
10.1.3. Key Insights
10.1.4. Key Strategy
10.1.5. Product Portfolio
10.1.6. SWOT Analysis
10.2. Immunomedics
10.2.1. Introduction
10.2.2. Financials
10.2.3. Key Insights
10.2.4. Key Strategy
10.2.5. Product Portfolio
10.2.6. SWOT Analysis
10.3. Seattle Genetics
10.3.1. Introduction
10.3.2. Financials
10.3.3. Key Insights
10.3.4. Key Strategy
10.3.5. Product Portfolio
10.3.6. SWOT Analysis
10.4. Bayer HealthCare AG
10.4.1. Introduction
10.4.2. Financials
10.4.3. Key Insights
10.4.4. Key Strategy
10.4.5. Product Portfolio
10.4.6. SWOT Analysis
10.5. Pfizer Inc.
10.5.1. Introduction
10.5.2. Financials
10.5.3. Key Insights
10.5.4. Key Strategy
10.5.5. Product Portfolio
10.5.6. SWOT Analysis
10.6. Roche/Genentech
10.6.1. Introduction
10.6.2. Financials
10.6.3. Key Insights
10.6.4. Key Strategy
10.6.5. Product Portfolio
10.6.6. SWOT Analysis
10.7. Novartis
10.7.1. Introduction
10.7.2. Financials
10.7.3. Key Insights
10.7.4. Key Strategy
10.7.5. Product Portfolio
10.7.6. SWOT Analysis
10.8. Heidelberg Pharma
10.8.1. Introduction
10.8.2. Financials
10.8.3. Key Insights
10.8.4. Key Strategy
10.8.5. Product Portfolio
10.8.6. SWOT Analysis
10.9. Oxford BioTherapeutics
10.9.1. Introduction
10.9.2. Financials
10.9.3. Key Insights
10.9.4. Key Strategy
10.9.5. Product Portfolio
10.9.6. SWOT Analysis
10.10. Agensys, Inc.
10.10.1. Introduction
10.10.2. Financials
10.10.3. Key Insights
10.10.4. Key Strategy
10.10.5. Product Portfolio
10.10.6. SWOT Analysis
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"

11. Appendix
11.1. Abbreviations
11.2. Sources
11.3. Research Methodology
11.4. Expert Insights
Note: Product cover images may vary from those shown
3 of 3


4 of 3